Brain Cancer clinical trials in Kansas

3 actively recruiting brain cancer trials at 5 sites across Kansas.

Data from ClinicalTrials.gov · last refreshed 2026-07-07

Phase 3 Recruiting Industry

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …

Sponsor: Nuvation Bio Inc.

NCT ID: NCT05303519

Sites in Kansas:

University of Kansas Medical Center — Kansas City, Kansas

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT04511013

Sites in Kansas:

Central Care Cancer Center - Garden City — Garden City, Kansas
Central Care Cancer Center - Great Bend — Great Bend, Kansas

View on ClinicalTrials.gov →

Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06860594

Sites in Kansas:

University of Kansas Clinical Research Center — Fairway, Kansas
University of Kansas Cancer Center — Kansas City, Kansas
University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07